Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

Outcomes in patients with therapy-Related AML who achieved remission with CPX...

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa...

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )

Selective oestrogen receptor degraders as treatment for ER positive/HER2...

Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer ( Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium )

SABCS 2019 highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

SABCS 2019 highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2...

Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer ( Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain )

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML...

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA

QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from...

Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia

Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study ( Prof Constantine Tam - Peter MacCallum Cancer Centre, Melbourne, Australia )

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with...

Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center...

ELEVATE TN: Comparing acalabrutinib monotherapy or in combination with obinutuzumab in treatment-naïve CLL ( Dr Jeff Sharman - Willamette Valley Cancer Institute and Research Center, Eugene, USA )

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell...

Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA

PRIMO: Optimising the dose of duvelisib in patients with R/R peripheral T-cell lymphoma ( Dr Steven Horwitz - Memorial Sloan Kettering Cancer Center, New York, USA )

Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory...

Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center

$Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )$

GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?

Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA

GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy? ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible...

Prof David Cairns - University of Leeds, Leeds, UK

FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM ( Prof David Cairns - University of Leeds, Leeds, UK )

More from ecancer